On Nov. 23rd, ACTC submitted an IND for using RPE technology for treating Stargardt's Disease. The CEO hopes that it will get final clearance by the end of Q1 2010.
Update from: Dan Schustack, Senior Analyst, CEOcast Inc.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.